Xu Zhao

Dr. Xu Zhao


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
DSDanni Song
Danni Song
XZXu Zhao
Xu Zhao
FWFuqi Wang
Fuqi Wang
GWGang Wang
Gang Wang

27 September 2022 in Journal of Food Biochemistry
Verified
Journal Article
Closed access
AMAijinxiu Ma
Aijinxiu Ma
FZFengmao Zou
Fengmao Zou
RZRuowen Zhang
Ruowen Zhang
XZXu Zhao
Xu Zhao

22 November 2021 in Food & Function
Verified
Journal Article
Closed access
PDF file
FWFuqi Wang
Fuqi Wang
XZXu Zhao
Xu Zhao
XSXin Su
Xin Su
DSDanni Song
Danni Song
FZFengmao Zou
Fengmao Zou
LFLina Fang
Lina Fang
Isorhamnetin, a main flavonoid component from the water extract of Sophorae Flos (an unopened dry flower bud ofSophora japonica), ameliorates uric acid levels and renal function by inhibiting XOD activity in hyperuricemic mice.

23 August 2021 in Journal of Food Biochemistry
Verified
Journal Article
Closed access
PDF file
FZFengmao Zou
Fengmao Zou
XZXu Zhao
Xu Zhao
FWFuqi Wang
Fuqi Wang

25 November 2023 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
ZHZihan Hou
Zihan Hou
AMAijinxiu Ma
Aijinxiu Ma
JMJiale Mao
Jiale Mao
DSDanni Song
Danni Song
XZXu Zhao
Xu Zhao
Hyperuricemia is a common metabolic disease, which is a risk factor for gouty arthritis and ureteral stones and may also lead to cardiovascular and chronic kidney disease (CDK). Therefore, hyperuricemia should be treated early. Xanthine oxidase inhibitors (XOIs) and uricosuric agents (UAs), which target uric acid, are two types of medications that are used to treat gout and hyperuricemia. XOIs stop the body from producing excessive uric acid, while UAs eliminate it rapidly via the kidneys. Urate transporter 1 (URAT1) belongs to the organic anion transporter family (OAT) and is specifically localized to the apical membrane of the epithelial cells of proximal tubules. Unlike other organic anion transporter family members, URAT1 identifies and transports organic anions that are primarily responsible for urate transport. This article reviews the pharmacokinetics and pharmacodynamics of the existing URAT1 inhibitors to serve as a reference for subsequent drug studies. The URAT1 inhibitors that are currently used as clinical drugs mainly include dotinurad, benzbromarone, and probenecid. Results indicate that RDEA3170 may be the mot promising inhibitor, in addition to SHR4640, URC-102, and MBX-102, which are in the early stages of development.

12 July 2018 in Molecules
Verified
Journal Article
Open access
PDF file
XZXu Zhao
Xu Zhao
XSXin Su
Xin Su
CLChunmei Liu
Chunmei Liu
YJYing Jia
Ying Jia
A simple and rapid ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) coupled with a one-step liquid-liquid extraction method has been developed and validated for the simultaneous determination of two flavonoids (chrysin, tectochrysin) from Alpinia oxyphylla fruits extract in rat plasma. Plasma samples were extracted with diethyl ether and separated on an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) using gradient elution consisting of 0.1% formic acid in water (A) and methanol (B). The multiple reaction monitoring (MRM) mode with electrospray ionization in the positive ion mode was used for detection. The linear range was 0.1 ng/mL to 50 ng/mL for chrysin and tectochrysin, respectively. The accuracy (relative error, RE%) ranged from −8.8% to 7.5% and the intra-day and inter-day precision were within 15% and had a mean extraction recovery rate of 80.3% to 86.7%. The validated method was applied to a comparative pharmacokinetic study after oral administration of Alpinia oxyphylla fruit ethanol extract between normal rats and dementia rats. The area under the curve (AUC) and peak plasma concentration (Cmax) of the two constituents were remarkably increased in dementia rats than in normal rats.